Fluticasone propionate/formoterol fumarate 100/10

DRUG3 trials

Sponsors

SkyePharma AG

Conditions

Asthma

Phase 3

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

CompletedNCT00394199

SkyePharma AGAsthma

Start: 2006-06-30End: 2008-02-29Updated: 2011-06-23

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

CompletedNCT00393952

SkyePharma AGAsthma

Start: 2006-06-30End: 2008-04-30Updated: 2011-06-23

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

CompletedNCT00393991

SkyePharma AGAsthma

Start: 2006-07-31End: 2008-04-30Updated: 2011-06-23

Related Papers

Fluticasone/Formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma.

2013-07-0116 citations

Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma.

2012-12-2538 citations

Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial.

2012-10-1829 citations